浩欧博(688656) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥104,222,613.66, a decrease of 4.92% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥6,581,954.35, down 61.42% year-on-year[2]. - The net profit excluding non-recurring gains and losses for Q3 2024 was ¥6,316,805.98, a decrease of 61.13% compared to the same period last year[3]. - The basic earnings per share for Q3 2024 was ¥0.11, a decline of 59.26% year-on-year[3]. - The company reported a decrease in net profit due to increased share-based payment expenses and clinical trial costs for new drug registrations[6]. - In the first three quarters of 2024, the net profit attributable to shareholders of the listed company decreased significantly, primarily due to increased investment in the desensitization drug "Otuoke," which rose by 10.95 million RMB compared to the same period last year[12]. - The share-based payment expenses increased by 11.45 million RMB in the first three quarters of 2024 compared to the previous year[13]. - If excluding the impact of the desensitization drug "Otuoke," the net profit attributable to shareholders decreased by 2.62% year-on-year, while the net profit excluding non-operating gains and losses increased by 5.55%[13]. - If excluding the impacts of both the desensitization drug "Otuoke" and the increased share-based payment expenses, the net profit attributable to shareholders increased by 23.02% year-on-year, and the net profit excluding non-operating gains and losses increased by 33.60%[13]. - Net profit for Q3 2024 was CNY 26,562,954.15, a decrease of 31.2% compared to CNY 38,633,884.75 in Q3 2023[18]. - Operating profit for Q3 2024 was CNY 30,123,137.88, down from CNY 43,360,389.54 in Q3 2023, reflecting a decline of 30.5%[18]. - Total profit for Q3 2024 was CNY 30,149,236.38, down 32.2% from CNY 44,470,130.53 in Q3 2023[18]. Revenue and Costs - Total operating revenue for the first three quarters of 2024 reached ¥307,033,592.46, a slight increase from ¥300,153,994.57 in the same period of 2023, representing a growth of approximately 2.9%[17]. - Total operating costs increased to ¥277,444,937.17 in 2024 from ¥260,338,591.77 in 2023, marking an increase of about 6.5%[17]. - Total revenue from sales and services received in the first three quarters of 2024 was CNY 329,442,738.27, up from CNY 317,609,730.26 in the same period of 2023, representing a growth of 3.3%[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,002,834,049.14, an increase of 5.64% compared to the end of the previous year[3]. - The company's total assets as of the end of Q3 2024 amounted to ¥1,002,834,049.14, compared to ¥949,256,814.47 at the end of Q3 2023, reflecting an increase of about 5.5%[16]. - Current liabilities totaled ¥184,046,707.37 in Q3 2024, up from ¥135,751,670.88 in Q3 2023, representing an increase of approximately 35.4%[16]. - The company's total equity as of Q3 2024 was ¥806,030,093.75, a slight decrease from ¥810,733,083.96 in Q3 2023, indicating a decline of about 0.3%[16]. - The company reported a significant increase in short-term borrowings, which rose to ¥95,044,825.41 in Q3 2024 from ¥50,024,293.23 in Q3 2023, an increase of approximately 90%[16]. - Deferred tax assets increased to ¥4,048,201.31 in Q3 2024 from ¥2,472,612.63 in Q3 2023, reflecting an increase of about 63.8%[16]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥76,353,980.20, an increase of 6.65% year-on-year[3]. - Cash flow from operating activities for the first three quarters of 2024 was CNY 76,353,980.20, an increase of 6.9% compared to CNY 71,594,957.40 in the same period of 2023[21]. - Cash flow from investing activities showed a net outflow of CNY 128,918,745.49 in Q3 2024, compared to a smaller outflow of CNY 12,418,999.48 in Q3 2023[21]. - The company’s cash flow from financing activities showed a net outflow of CNY 5,611,417.69 in Q3 2024, an improvement from a net outflow of CNY 25,069,502.07 in Q3 2023[21]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 2,621[7]. - The largest shareholder, Hai Rui Xiang Tian Biotechnology (Group) Co., Ltd., holds 35,100,000 shares, accounting for 55.66% of the total shares[7]. - The top ten shareholders include Hai Rui Xiang Tian Bio-Tech Group Co., Ltd., holding 35.1 million shares, representing a significant portion of the company's equity[10]. - The company repurchased 801,314 shares, accounting for 1.27% of the total share capital[10]. Research and Development - Research and development expenses totaled ¥11,341,569.83, representing 10.88% of operating revenue, a decrease of 0.79 percentage points from the previous year[3]. - Research and development expenses for the first three quarters of 2024 were ¥33,952,496.52, slightly down from ¥35,386,698.65 in 2023, indicating a decrease of approximately 4%[17]. Cash and Equivalents - As of September 30, 2024, cash and cash equivalents amounted to 105.13 million RMB, down from 163.47 million RMB at the end of 2023[14]. - The net cash and cash equivalents at the end of Q3 2024 were CNY 105,131,329.06, down from CNY 187,510,918.21 at the end of Q3 2023, a decrease of 43.8%[22]. Foreign Exchange - The company incurred a foreign exchange loss of CNY 156,482.86 in Q3 2024, compared to a gain of CNY 100,874.94 in Q3 2023[22].